Gastroparesis Management Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2015-2020 and Forecast 2021-2027

$ PRICE - $ 3,000.00$ 8,900.00

Global Gastroparesis Management Market by Intervention Type (Drugs, Surgical Treatment), by Cause (Idiopathic Gastroparesis, Diabetic Gastroparesis, Surgery,Nervous System Disorders, Others), by Gastroparesis Type (Acute Gastroparesis, Recurrent gastroparesis), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, E-Commerce) and Geogrpahy

 

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail

Report

Description

The global gastroparesis management market size is expected to reach US$ 6,035.11 million by 2027 from US$ 4,348.61 million in 2021 at a CAGR of 4.6% from 2021 to 2027. Gastroparesis is also called as delayed gastric emptying, is a disorder of stomach that hinder the movement of food from stomach to small intestine. Generally, muscles of the GI tract controlled by the vagus nerve, that contract to move the food contents throughout the GI tract. Gastroparesis occurs when vagus nerve damaged by illness or the injury which leads to slower movement of food contents from the stomach to the small intestine. Majority of people with gastroparesis have idiopathic gastroparesis of which cause is unknown. Diabetes is commonly known the cause of gastroparesis. Elevated sugar levels in diabetics believed to cause damage of vagus nerve and other causes of gastroparesis include gastric surgery, Parkinson’s diseases, and multiple sclerosis. Gastroparesis generally found in females than males. The gastroparesis management market report evaluates all-inclusive data that enriches the scope, understanding and application of this report. Gastroparesis is a condition that primarily affects diabetics with type 1 and type 2 diabetes. The stomach takes an abnormally long time to empty its contents in this condition. Gastroparesis is treated with drugs such as erythromycin, antiemetics, and Reglan. Furthermore, due to the increased prevalence of type 1 and type 2 diabetes, which may increase the risk of gastroparesis, there are 119 completed and continuing clinical trials for gastroparesis medicines. This increases the demand for these drugs and, to some extent, fuels the total market. However, the market may be hampered by adverse effects associated with gastroparesis medications.


Gastroparesis Management Market

MARKET SUMMARY
-
4.6%
  • Study Period– 2021 – 2027
  • Base Year– 2020
  • CAGR– 4.6%
  • Largest Market– North America
  • Fastest Growing Market– Asia-Pacific

Gastroparesis Management Market

  • The report on global gastroparesis management market gives historical, current, and future market sizes (US$ Mn) on the basis of by Intervention type, by Cause, by Gastroparesis, by Distribution Channel and geography.
  • gastroparesis management market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, ,America and Middle East and Africa.
Key Players
  • Abbott Laboratories,
  • Boston Scientific Corporation,
  • C. R. Bard, Inc.,
  • Evoke Pharma
  • Salix Pharmaceuticals, Inc.,
  • Janssen Global Services, LLC,
  • Medtronic,
  • Kimberly-Clark Corporation,
  • Rhythm Pharmaceuticals, Inc.

 

Drivers and Restrains

Gastroparesis Management Market

Rising prevalence of diabetes and gastroparesis, increasing gastroparesis awareness among healthcare professionals expected to propel market for gastroparesis management market over the forecast period. Moreover, rising clinical development candidates for treating gastroparesis is expected to fuel the market revenue for gastroparesis management market. For instance, as of now, there are around six drug candidates in clinical development which act by different mechanisms and route of administration. However, a dearth of specific treatment options, large medical unmet need, and lack of gastroparesis management guidelines expected to hamper the Gastroparesis Management Market over the forecast period.


North-America got significant share

Gastroparesis Management Market

North America, Europe, Asia Pacific, Latin America and the Middle East and Africa. North America gastroparesis market is driven by increasing prevalence of disease and potentially 12-16 Mn patients are believed to suffering from gastroparesis in the region. Asia Pacific market expected to grow at significant rate owing to the higher prevalence of diabetes in the region. Asian countries contribute around 60% of the world diabetes population which is expected to drive the market revenue growth. Europe market for gastroparesis management expected to grow at moderate CAGR over forecast period.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Report Outline

  • The report provides granular level information about the market size, regional market share, and forecast from 2020-2026
  • The report covers in-detail insights about the competitor’s overview, key findings, and their key strategies
  • The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
  • The report tracks recent innovations, key developments, and startup’s details that are working in the industry
  • The report provides plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Key

Notable Market Developments

Gastroparesis Management Market Segmentation


Location

GEOGRAPHY


Report

Table Of Content


Report

Company Profile

  • Abbott Laboratories
  • Salix Pharmaceuticals, Inc.
  • Janssen Global Services, LLC
  • Medtronic
  • Kimberly-Clark Corporation
  • C. R. Bard, Inc.
  • Boston Scientific Corporation
  • Rhythm Pharmaceuticals, Inc.
  • Evoke Pharma

Description

The global gastroparesis management market size is expected to reach US$ 6,035.11 million by 2027 from US$ 4,348.61 million in 2021 at a CAGR of 4.6% from 2021 to 2027. Gastroparesis is also called as delayed gastric emptying, is a disorder of stomach that hinder the movement of food from stomach to small intestine. Generally, muscles of the GI tract controlled by the vagus nerve, that contract to move the food contents throughout the GI tract. Gastroparesis occurs when vagus nerve damaged by illness or the injury which leads to slower movement of food contents from the stomach to the small intestine. Majority of people with gastroparesis have idiopathic gastroparesis of which cause is unknown. Diabetes is commonly known the cause of gastroparesis. Elevated sugar levels in diabetics believed to cause damage of vagus nerve and other causes of gastroparesis include gastric surgery, Parkinson’s diseases, and multiple sclerosis. Gastroparesis generally found in females than males. The gastroparesis management market report evaluates all-inclusive data that enriches the scope, understanding and application of this report. Gastroparesis is a condition that primarily affects diabetics with type 1 and type 2 diabetes. The stomach takes an abnormally long time to empty its contents in this condition. Gastroparesis is treated with drugs such as erythromycin, antiemetics, and Reglan. Furthermore, due to the increased prevalence of type 1 and type 2 diabetes, which may increase the risk of gastroparesis, there are 119 completed and continuing clinical trials for gastroparesis medicines. This increases the demand for these drugs and, to some extent, fuels the total market. However, the market may be hampered by adverse effects associated with gastroparesis medications.

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX